[2] https://www.cancer.gov/types/prostate/hp/prostate-screening-pdq [3] Landy, R., Houghton, L. C., Berg, C. D., Grubb, R. L., 3rd, Katki, H. A., & Black, A. (2020). Risk of Prostate Cancer-related Death Following a Low PSA Level in the PLCO Trial. Cancer prevention ...
我国转移性激素敏感性前列腺癌(mHSPC)患者基线状态复杂,PSA达标率仅约50%[1,2],5年生存率仅约35%[3],严重威胁我国老年男性健康。近年来,达罗他胺等新型雄激素受体抑制剂(ARi)为前列腺癌内分泌治疗提供了更多选择,已成为mHSPC的...
The trends are startlingly different. The incidence of metastatic prostate cancer fell by approximately 50% within 7 years of the start of widespread PSA use in 1990; however, rates of metastatic breast cancer remained remarkably stable following the initiation of widespread mammography screening in w...
Introduction: Prostate cancer is the sixth most common cancer in the world, the second most common cancer among men, and the most common cancer in men in Europe. Metastatic prostate cancer among young patients represents the rarest of the newly diagnosed prostate cancer, with few reports of ...
A Phase 2 Study of an Allogeneic GM-CSF Gene-Transduced Prostate Cancer Cell Line Vaccine in Patients with Metastatic Hormone-Refractory Prostate Cancer Small E, Higano C, Smith D: A phase 2 study of an allogeneic GM-CSF gene-transduced prostate cancer cell line vaccine in patients with meta...
prostate cancer: thelevelofserumPSApositivelycorrelatedandclinical stageofprostatecancer(r= 0.916,P<0.01). The relationship betweenPSAratiofor prostate CanCerandGleasonscore:PSA ratioandGleasonscoreintheoverall negativecorrelation(r=・ 0.560,P<0.01);in ...
[1] Saad F, Hussain MHA, Tombal B, et al. Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High-...
Abiraterone (AA) is indicated in mRCPC (metastatic castration-resistant prostate cancer) before or after chemotherapy, and in mHSPC (metastatic hormone-sensitive prostate cancer) as first line. A decrease in PSA is associated with improved clinical response and increased survival. Recent studies have...
5 However, the rate of metastatic disease was reduced by 2.4 per 1000 person-years with surgery and by 3.0 per 1000 person-years with radiotherapy vs by 6.3 per 1000 person-years with active monitoring. Given the very low disease-specific mortality at 10 years and the long lead time for ...
A false-negative PSA test result can also occur. PSA levels can be low even though you actually have prostate cancer. False-negative test results may give you false assurance. If I choose PSA testing, what are the next steps if you have a raised PSA level?